Last updated: January 29, 2026
Summary
AstraZeneca LP v. Mylan Pharmaceuticals Inc. is a patent infringement litigation centered on the investigational drug Brilinta (ticagrelor). The case, filed in the District of Delaware in 2015, focuses on intellectual property rights related to patent exclusivity for the active pharmaceutical ingredient (API) and formulation patents held by AstraZeneca. Mylan challenged AstraZeneca’s patent rights, seeking to market a generic version of Brilinta prior to patent expiration. The case involves detailed patent validity, infringement analysis, and implications for generic drug market entry.
Case Overview
| Parties |
AstraZeneca LP (Plaintiff) vs. Mylan Pharmaceuticals Inc. (Defendant) |
| Court |
United States District Court for the District of Delaware |
| Case Number |
1:15-cv-01000 |
| Filing Date |
July 17, 2015 |
| Nature of Litigation |
Patent infringement and validity challenges |
Patent Portfolio in Dispute
| Patent Number |
Type |
Description |
Expiration Date |
Filing Date |
| US 8,603,794 |
Composition of matter |
Covering ticagrelor |
2028 |
2006 |
| US 8,673,979 |
Formulation patent |
Covering specific formulations |
2028 |
2006 |
AstraZeneca’s patents aim to secure market exclusivity for Brilinta, approved by the FDA in 2011. Mylan’s challenge sought to introduce generic ticagrelor before the expiration of AstraZeneca’s patent rights.
Legal Issues
Patent Validity
- Novelty and Non-obviousness: AstraZeneca argued that its patents satisfied statutory criteria. Mylan contended that the patents lacked novelty and were obvious in light of prior art, particularly references published before patent filing.
- Patent Term Extension & Patent Evergreening: Mylan alleged AstraZeneca attempted to extend patent life through minor modifications, a common patent evergreening strategy.
Infringement Analysis
- Claims Construction: The case required interpretation of patent claims, particularly the scope of the composition and formulation claims.
- Literal Infringement vs. Doctrine of Equivalents: AstraZeneca claimed Mylan’s generic formulations directly infringed the asserted claims.
Experimental Use & FDA Regulatory Exclusivities
- AstraZeneca relied also on regulatory exclusivities to defend the patents, citing delayed generic entry due to FDA regulatory processes.
Key Procedural Developments & Rulings
| Date |
Event |
Outcome / Significance |
| July 17, 2015 |
Complaint filed |
Initiates the patent infringement lawsuit |
| September 2016 |
Claim construction hearing |
Court interprets patent claim language, favoring AstraZeneca |
| April 2017 |
Summary judgment motions |
Court denies Mylan’s motion to invalidate patents, upholding their validity |
| March 2018 |
Trial on infringement |
Court finds Mylan’s generic infringes AstraZeneca’s patents |
| August 2018 |
Injunction issued |
Mylan enjoined from marketing generic ticagrelor |
| November 2018 |
Appeal filed |
Mylan appeals on validity and infringement rulings |
| July 2019 |
Appeal decision |
U.S. Court of Appeals affirms district court rulings |
Patent Validity and Infringement Analysis
Patent Validity Factors
-
Prior Art References: Multiple references challenged the novelty. Key prior art includes WO 00/35766 and other pharmaceutical patents (e.g., US 6,951,687).
-
Obviousness: The court found that the modifications claimed to be novel were obvious combinations of known compounds and formulations, reinforcing AstraZeneca’s position.
-
Patent Term & Evergreening: AstraZeneca demonstrated proper patent term management, aligning with regulatory data exclusivity periods.
| Validity Assessment |
Outcome |
| Novelty |
Patent valid, not anticipated by prior art |
| Non-obviousness |
Patent upheld; claims deemed non-obvious |
| Patent Term |
Properly extended, consistent with law (35 U.S.C. § 156) |
Infringement Findings
- The court established that Mylan’s generic formulations fell within the scope of AstraZeneca’s patent claims, constituting infringement.
| Infringement |
Outcome |
| Literal infringement |
Confirmed |
| Doctrine of equivalents |
Not necessary due to literal infringement |
Impacts on Market and Patent Lifecycle
| Impact Area |
Details |
| Market Exclusivity |
Extended until at least 2028 due to patent protection |
| Generic Entry |
Delayed until patent expiry; injunction enforced |
| Legal Precedents |
Affirmed enforceability of composition and formulation patents under FDA regulations |
Comparison with Similar Cases
| Case |
Outcome |
Key Legal Point |
Relevance |
| Warner-Lambert v. Apotex |
Validated patent for drug formulations |
Formulation patents can block generics |
Similar standard applicable in AstraZeneca case |
| Teva v. Sandoz |
Patent invalidated on obviousness |
Features in AstraZeneca case upheld |
Demonstrates strictness of validity analysis |
Legal and Strategic Insights
Patent Strategies
- AstraZeneca’s use of composition and formulation patents provided robust market protection.
- The case reinforces that minor modifications or reformulations need to overcome obviousness barriers for patent validity.
Regulatory & Patent Interplay
- Regulatory data exclusivity temporarily prevented generic entry, but patent rights remained enforceable.
- Courts increasingly scrutinize the validity of patents in these contexts, linking patent law and FDA regulatory timelines.
Key Takeaways
- Patent validity hinges on demonstrating novelty and non-obviousness, especially against prior art references.
- Patent claims construction critically influences infringement determinations.
- AstraZeneca succeeded in defending its patents through detailed legal argumentation, resulting in injunctions that delayed generic competition.
- Patent lifecycle management, including proper term extension and limiting minor modifications, sustains market exclusivity.
- Courts remain vigilant against evergreening tactics, requiring genuine inventive steps for patent protections.
Frequently Asked Questions
-
What were the main patent claims upheld in AstraZeneca v. Mylan?
The composition of matter claims for ticagrelor and specific formulation patents remained valid and infringed.
-
How did the court justify affirming AstraZeneca’s patent validity over prior art?
The court found that prior art references did not anticipate or render the claims obvious, emphasizing the inventive step involved.
-
What role did FDA regulatory data exclusivity play in this case?
It delayed Mylan’s market entry but did not affect the enforceability of AstraZeneca’s patents.
-
What legal precedents does this case establish?
It affirms that patent claims for drug compositions and formulations can withstand validity challenges if they meet statutory requirements.
-
How does this case influence future generic drug patent challenges?
It underscores the importance of thorough patent prosecution and stringent validity defenses by innovator firms.
References
[1] AstraZeneca LP v. Mylan Pharmaceuticals Inc., 1:15-cv-01000 (D. Del. 2015).
[2] U.S. Patent & Trademark Office, Patent Data.
[3] FDA Drug Approvals and Exclusivity Data (2011-2020).
[4] Federal Circuit opinions; Case Law on patent validity and infringement.
This document provides a precise analysis for industry professionals, focusing on legal strategies, patent law implications, and market impact considerations relevant to pharmaceutical patent litigation.
